287 related articles for article (PubMed ID: 10971520)
1. Up-regulation of the tumour-associated marker CD44V6 in experimental kidney disease.
Takazoe K; Foti R; Tesch GH; Hurst LA; Lan HY; Atkins RC; Nikolic-Paterson DJ
Clin Exp Immunol; 2000 Sep; 121(3):523-32. PubMed ID: 10971520
[TBL] [Abstract][Full Text] [Related]
2. CD44 and hyaluronan expression in the development of experimental crescentic glomerulonephritis.
Jun Z; Hill PA; Lan HY; Foti R; Mu W; Atkins RC; Nikolic-Paterson DJ
Clin Exp Immunol; 1997 Apr; 108(1):69-77. PubMed ID: 9097914
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197.
Kuncová J; Kostrouch Z; Viale M; Revoltella R; Mandys V
Folia Biol (Praha); 2005; 51(1):3-11. PubMed ID: 15783086
[TBL] [Abstract][Full Text] [Related]
4. CD44 variant exons in leukemia and lymphoma.
Akisik E; Bavbek S; Dalay N
Pathol Oncol Res; 2002; 8(1):36-40. PubMed ID: 11994761
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
[TBL] [Abstract][Full Text] [Related]
6. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation.
Isbel NM; Hill PA; Foti R; Mu W; Hurst LA; Stambe C; Lan HY; Atkins RC; Nikolic-Paterson DJ
Kidney Int; 2001 Aug; 60(2):614-25. PubMed ID: 11473644
[TBL] [Abstract][Full Text] [Related]
7. Transient expression of CD44 variant isoforms in the ontogeny of the rat: ectoderm-, endoderm- and mesoderm-derived cells express different exon combinations.
Weber B; Rösel M; Arch R; Möller P; Zöller M
Differentiation; 1996 Mar; 60(1):17-29. PubMed ID: 8935925
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
9. Expression of exon v6-containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia.
Yokota A; Ishii G; Sugaya Y; Nishimura M; Saito Y; Harigaya K
Hematol Oncol; 1998 Dec; 16(4):131-41. PubMed ID: 10414233
[TBL] [Abstract][Full Text] [Related]
10. Variant expression of CD44 in preneoplastic lesions of the lung.
Wimmel A; Kogan E; Ramaswamy A; Schuermann M
Cancer; 2001 Sep; 92(5):1231-6. PubMed ID: 11571737
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 variants in osteosarcoma.
Kuryu M; Ozaki T; Nishida K; Shibahara M; Kawai A; Inoue H
J Cancer Res Clin Oncol; 1999 Nov; 125(11):646-52. PubMed ID: 10541973
[TBL] [Abstract][Full Text] [Related]
12. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
Liu YJ; Yan PS; Li J; Jia JF
World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
[TBL] [Abstract][Full Text] [Related]
13. CD44 expression and regulation during mammary gland development and function.
Hebbard L; Steffen A; Zawadzki V; Fieber C; Howells N; Moll J; Ponta H; Hofmann M; Sleeman J
J Cell Sci; 2000 Jul; 113 ( Pt 14)():2619-30. PubMed ID: 10862719
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic renal cells are the major source of interleukin-1 beta synthesis in normal and diseased rat kidney.
Tesch GH; Yang N; Yu H; Lan HY; Foti R; Chadban SJ; Atkins RC; Nikolic-Paterson DJ
Nephrol Dial Transplant; 1997 Jun; 12(6):1109-15. PubMed ID: 9198037
[TBL] [Abstract][Full Text] [Related]
15. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma.
van Hal NL; van Dongen GA; Stigter-van Walsum M; Snow GB; Brakenhoff RH
Int J Cancer; 1999 Sep; 82(6):837-45. PubMed ID: 10446451
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer.
Aaltomaa S; Lipponen P; Ala-Opas M; Kosma VM
Eur Urol; 2001 Feb; 39(2):138-44. PubMed ID: 11223672
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation.
Khan SA; Cook AC; Kappil M; Günthert U; Chambers AF; Tuck AB; Denhardt DT
Clin Exp Metastasis; 2005; 22(8):663-73. PubMed ID: 16691370
[TBL] [Abstract][Full Text] [Related]
19. SR proteins regulate V6 exon splicing of CD44 pre-mRNA.
Loh TJ; Moon H; Jang HN; Liu Y; Choi N; Shen S; Williams DR; Jung DW; Zheng X; Shen H
BMB Rep; 2016 Nov; 49(11):612-616. PubMed ID: 27530682
[TBL] [Abstract][Full Text] [Related]
20. CD44v6 cell surface expression is a common feature of macrophages and macrophage-like cells - implication for a natural macrophage extravasation mechanism mimicked by tumor cells.
Braumüller H; Gansauge S; Ramadani M; Gansauge F
FEBS Lett; 2000 Jul; 476(3):240-7. PubMed ID: 10913621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
